Source:http://linkedlifedata.com/resource/pubmed/id/16121204
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2005-12-15
|
| pubmed:abstractText |
Ovarian cancer represents the fifth leading cause of cancer death among women in the United States, with >16 000 deaths expected this year. This study was carried out to investigate the potential of sodium iodide symporter (NIS)-mediated radioiodide therapy as a novel approach for ovarian cancer treatment. Radioiodide is routinely and effectively used for the treatment of benign and malignant thyroid disease as a result of native thyroidal expression of NIS, which mediates iodide uptake. In vitro gene transfer studies in ovarian cancer cells revealed a 12- and five-fold increase in iodide uptake when transduced with Ad/CMV/NIS or Ad/MUC1/NIS, respectively. Western blot/immunohistochemistry confirmed NIS protein expression. In vivo ovarian tumor xenografts were infected with the adenoviral constructs. (123)I imaging revealed a clear image of the CMV/NIS-transduced tumor, with a less intense image apparent following infection with MUC1/NIS. Therapeutic doses of (131)I following CMV/NIS infection caused a mean 53% reduction in tumor volume (P<0.0001). MUC1/NIS-transduced tumors did not regress, although at 8 weeks following therapy, tumor volume was significantly less that of control animals (166 versus 332%, respectively, P<0.05). This study represents a promising first step investigating the potential for NIS-mediated radioiodide imaging and therapy of ovarian tumors.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0969-7128
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
13
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
60-6
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:16121204-Adenoviridae,
pubmed-meshheading:16121204-Animals,
pubmed-meshheading:16121204-Blotting, Western,
pubmed-meshheading:16121204-Cell Line, Tumor,
pubmed-meshheading:16121204-Female,
pubmed-meshheading:16121204-Gene Therapy,
pubmed-meshheading:16121204-Genetic Vectors,
pubmed-meshheading:16121204-Humans,
pubmed-meshheading:16121204-Immunohistochemistry,
pubmed-meshheading:16121204-Iodine Radioisotopes,
pubmed-meshheading:16121204-Mice,
pubmed-meshheading:16121204-Mucin-1,
pubmed-meshheading:16121204-Neoplasm Transplantation,
pubmed-meshheading:16121204-Ovarian Neoplasms,
pubmed-meshheading:16121204-Promoter Regions, Genetic,
pubmed-meshheading:16121204-Symporters,
pubmed-meshheading:16121204-Transduction, Genetic,
pubmed-meshheading:16121204-Transplantation, Heterologous
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice.
|
| pubmed:affiliation |
Department of Endocrinology, Mayo Clinic, Rochester, MN 55905, USA.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|